Completed
PHASE3
INTERVENTIONAL
NCT04255433
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Dulaglutide
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)
TimeFrame:
Randomization up to Study Completion (Approximate Maximum 54 Months)
Description:
Time to First Occurrence of a component event of MACE-3
Trial Information
NCT ID
NCT04255433
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025